文献速递类风湿关节炎

早期类风湿关节炎低剂量糖皮质激素十年严重结局风险分析

Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于ESPOIR早期关节炎队列608例患者十年随访,65%接受低剂量糖皮质激素(中位1.9 mg/天)。单因素分析显示用药组严重结局事件多于未用药组,且累积暴露≥8.4 g与最高风险相关;糖皮质激素相关风险从1年HR 0.46增至10年HR 6.83。

要点

  • 低剂量糖皮质激素长期严重结局风险呈剂量和时间依赖性升高。
  • 累积泼尼松≥8.4 g与主要结局、心血管病和严重感染风险最高相关。
  • 糖皮质激素相关风险从1年HR 0.46增至10年HR 6.83。

核心结论

  • 早期RA患者低剂量糖皮质激素治疗与长期严重结局高风险相关,呈剂量和时间依赖性影响。

研究设计与样本

  • ESPOIR早期关节炎前瞻性队列的10年结局分析,纳入608例患者,按随访期间是否至少一次使用糖皮质激素分组。
  • 采用IPTW倾向评分加权的Cox时间依赖模型分析。

主要发现

  • 608例患者中480例女性,平均年龄47.5(12.1)岁,397例(65%)接受低剂量糖皮质激素。
  • 糖皮质激素中位剂量1.9 mg/天(IQR 0.6-4.2),平均累积泼尼松剂量8468 mg(8376),平均疗程44.6个月(40.1)。
  • 单因素分析共95起事件(10例死亡、18例心血管病、32例骨折、35例严重感染),用药组71起多于未用药组24起(P=0.035)。
  • 累积暴露≥8.4 g与主要结局发生率24.3%(P=0.007)、心血管病7.9%(P=0.001)、严重感染9.9%(P=0.024)最高风险相关。
  • 糖皮质激素相关风险从1年HR=0.46(95%CI: 0.23, 0.90)增至10年HR=6.83(95%CI: 2.29, 20.35)。

临床怎么用

  • 对早期RA使用低剂量糖皮质激素应权衡长期严重结局风险,关注累积剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the 10-year tolerability profile of glucocorticoids (GC) use in patients with early RA. METHODS: Analysis of 10-year outcome from the early arthritis ESPOIR cohort. Patients were stratified in two groups, without or with GC treatment at least once during their follow-up. The primary outcome was a composite of deaths, cardiovascular diseases (CVD), severe infections and fractures. The weighted Cox time-dependent analysis model was used with inverse probability of treatment weighting (IPTW) propensity score method. RESULTS: Among the 608 patients [480 women, mean age of 47.5 (12.1) years], 397 (65%) received low-dose GC [median 1.9 mg/day (IQR 0.6-4.2), mean cumulative prednisone dose 8468 mg (8376), mean duration 44.6 months (40.1)]. In univariate analysis, over 95 total events (10 deaths, 18 CVDs, 32 fractures and 35 severe infections), patients taking GC experienced more events (n = 71) than those without GC (n = 24) (P =0.035). Highest cumulative exposure of GC (≥8.4 g) was associated with highest risk of occurrence of the primary outcome (24.3%, P =0.007), CVDs (7.9%, P =0.001) and severe infections (9.9%, P =0.024). The risk of events over time was significantly associated with GC, age, hypertension and ESR. The risk associated with GC treatment increased between the first follow-up visit [hazard ratio (HR) at 1 year = 0.46, 95% CI: 0.23, 0.90] and 10 years (HR = 6.83, 95% CI: 2.29, 20.35). CONCLUSION: The 10-year analysis of this prospective early RA cohort supports a dose and time-dependent impact of low-dose GC treatment, with a long-term high risk of severe outcomes. TRIAL REGISTRATION: (ClinicalTrials.gov Identifier: NCT03666091).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Roubille C, Coffy A, Rincheval N, et al. Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2021. PMID: 33320245. doi:10.1093/rheumatology/keaa850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。